This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Fycompa

Eisai Co., Ltd.

Drug Names(s): E2007, perampanel

Description: E2007 blocks the AMPA receptor for glutamate, which is widely found in the brain and may be involved in a variety of functions. In Parkinson disease, glutamate has been implicated as a causal factor in nerve degeneration, certain motor and non-motor symptoms, and dyskinesias related to levodopa treatment.

Deal Structure: Eisai and Hikma
In October 2014, Hikma announced a partnership with Eisai for the distribution of Fycompa (perampanel) in the Middle East. The partnership will commence immediately, with perampanel launches throughout the region expected to follow in 2015.

Partners: Hikma Pharmaceuticals plc


Fycompa News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug